Antiviral Drugs Market to Reach USD 95.4 Billion by 2035 Driven by HIV Treatments and Innovative Therapies

The global antiviral drugs market is witnessing sustained expansion as healthcare systems worldwide respond to the increasing prevalence of viral infections. Estimated at USD 66.3 billion in 2025, the market is expected to reach USD 95.4 billion by 2035, growing at a compound annual growth rate of 3.7%. This growth reflects not only rising incidences of HIV, hepatitis, and influenza but also ongoing advancements in antiviral therapies, including combination treatments, targeted formulations, and long-acting drug options that enhance patient outcomes while reducing side effects.

The period between 2025 and 2035 will see hospitals and healthcare providers playing a central role in the administration of antiviral therapies. Hospitals alone are projected to account for 47.8% of market revenue in 2025, highlighting their importance in diagnosis, treatment initiation, and continuous patient management. With structured treatment protocols, advanced diagnostic tools, and specialized infectious disease units, hospitals remain the primary channel for delivering effective antiviral care.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-1951

Segmental Insights: HIV Antivirals Leading the Market

Among product segments, HIV antivirals are expected to dominate, accounting for 44% of market revenue in 2025. This segment benefits from the high prevalence of HIV infections worldwide, coupled with the urgent need for effective long-term management solutions. HIV antivirals help suppress viral loads, reduce transmission risks, and improve survival rates. Advances in single-tablet regimens and combination therapies have further enhanced adherence and clinical outcomes, while both branded and generic options have improved accessibility across diverse regions.

Research into novel drug classes, long-acting formulations, and safer treatment profiles continues to reinforce confidence in HIV antivirals. Strategic collaborations among pharmaceutical companies, research institutions, and healthcare organizations are accelerating development and distribution, ensuring that the segment maintains its leading market position.

Rising Demand for Antiviral Drugs

The growing demand for antiviral drugs is driven by both the increasing prevalence of viral infections and the urgent need for effective therapeutic interventions. According to UNAIDS, over 37 million people were living with HIV in 2024, with nearly 650,000 new cases recorded globally. Sub-Saharan Africa continues to see significant treatment adoption, with approximately four out of five newly diagnosed individuals receiving therapy, and two-thirds of HIV-positive pregnant women accessing antiretroviral drugs to prevent mother-to-child transmission.

In addition to HIV, the market is responding to influenza, herpes, and hepatitis infections, all of which require timely and effective antiviral interventions. Rising awareness around early diagnosis, routine testing, and long-term disease management has further contributed to the adoption of antiviral therapies. COVID-19 also highlighted the urgent need for antiviral drugs, prompting governments and private companies to invest heavily in research, development, and emergency distribution initiatives.

Regional Growth Dynamics

North America is expected to retain its leading position in the antiviral drugs market, contributing 38.7% of global revenue in 2025. The United States and Canada are the primary drivers, supported by strong healthcare infrastructure, ongoing R&D investments, and government initiatives aimed at reducing viral infection prevalence. Strategic funding programs and grants are enhancing the development of novel therapies, while vaccination campaigns and public health measures are complementing antiviral treatment strategies.

Europe holds the second-largest share, with 24.9% of the market in 2025. The region’s growth is fueled by investments in new drug development, streamlined regulatory approvals, and favorable healthcare policies. Notable initiatives include joint procurement agreements and emergency approvals for antiviral drugs, such as Merck’s COVID-19 antiviral pill and GSK’s sotrovimab, which support rapid response to public health emergencies. Germany, France, and the UK are leading markets within Europe, driven by advanced healthcare systems, facility modernization, and a focus on clinical efficacy and patient safety.

The Asia-Pacific region is projected to experience the fastest growth during the forecast period. Rising viral infection rates, expanding healthcare infrastructure, and growing public awareness are significant drivers. Countries such as India and China benefit from a strong presence of generic pharmaceutical manufacturers and increasing government support for healthcare initiatives. In addition, the region’s aging population and growing middle class are boosting the demand for accessible and effective antiviral therapies.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1951

Innovations and New Technologies

The antiviral drugs market is experiencing significant innovation, with research focusing on improved drug formulations, combination therapies, and vaccines. New approaches include long-acting injectables, biologics, and personalized medicine strategies that optimize efficacy and reduce side effects. Such innovations are expanding treatment options across viral categories, including HIV, hepatitis, and emerging infectious diseases.

Start-ups and specialized pharmaceutical companies are also contributing to market expansion. Companies like New American Therapeutics and Adaptive Biotechnologies in the United States are pioneering new therapeutic approaches, including topical antiviral drugs, immune profiling technologies, and novel vaccine candidates. These organizations are enhancing the research ecosystem, complementing efforts by established global players such as Roche, Gilead, GlaxoSmithKline, Bristol-Myers Squibb, Abbott, AstraZeneca, Cipla, Bayer, Johnson & Johnson, Merck & Co., AbbVie, Aurobindo Pharma, and Dr. Reddy’s Laboratories.

Competitive Landscape

The market is highly competitive, featuring a blend of multinational pharmaceutical giants and emerging regional players. Established companies are focusing on expanding their antiviral portfolios through innovation, strategic partnerships, and global distribution networks. Gilead’s introduction of Veklury for pediatric patients and Roche’s Xofluza approval for influenza highlight the focus on diversified antiviral offerings. Meanwhile, Cipla and Abbott are actively developing diagnostic tools and expanding production capabilities to enhance market accessibility.

Collaborations and partnerships are central to competitive strategies. Scripps Research and AbbVie’s collaboration to investigate immediate antiviral treatments for COVID-19 exemplifies the ongoing synergy between research institutions and pharmaceutical manufacturers. Such collaborations are expected to accelerate pipeline development and ensure that innovative therapies reach patients more efficiently.

Related Reports:

Multi-Parameter Patient Monitoring Market: https://www.futuremarketinsights.com/reports/multi-parameter-patient-monitoring-market

Medical Physics Market: https://www.futuremarketinsights.com/reports/medical-physics-market

Dialyzer Reprocessing Machines and Concentrates Market: https://www.futuremarketinsights.com/reports/dialyzer-reprocessing-machines-and-concentrates-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:     

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs | YouTube